Abstract 1013TiP
Background
Prompt detection of hepatocellular carcinoma (HCC) in patients with chronic liver diseases is critical for enhancing prognosis. Existing imaging techniques and serum markers fall short of clinical needs. This study aims to establish a non-invasive GAMAD test model for early HCC detection by incorporating demographic data (Gender and Age), circulating tumor DNA (ctDNA) Methylation signature in blood, and commonly utilized serum biomarkers [alpha-fetoprotein (AFP), des-γ-carboxy-prothrombin (DCP)]. Additionally, the study will evaluate the model's effectiveness among HCC patients at various stages and/or high-risk HCC groups.
Trial design
This prospective, multicenter, non-interventional study will enroll 2,000 participants, including HCC patients, those with chronic liver diseases (hepatitis, cirrhosis, and benign liver space-occupying lesions), and healthy individuals. Blood samples from all participants will be divided into training and validation sets (1,400 and 600 cases, respectively) for the development and blind validation of the GAMAD (Gender + Age + Methylation + AFP + DCP) HCC-discriminating classifier. The classifier's accuracy and utility will be further assessed in the entire cohort (training and validation cohort). Primary outcome endpoints include sensitivity, specificity, and accuracy [ROC curves; area under the curve (AUC) value] of GAMAD for HCC (in early and each stage) and/or high-risk HCC groups. Secondary outcome endpoints involve comparing GAMAD with the established GALAD model and individual blood indices (AFP, DCP, and methylation testing) to evaluate: (1) GAMAD's clinical utility and significance for HCC patients in early and other stages (according to different staging systems: TNM staging, the Milan criteria, and the BCLC staging criteria); (2) GAMAD's discrimination ability for patients in various subgroups, including liver cirrhosis (LC) related HCC and LC, HBV related HCC and HBV, HCV related HCC and HCV, and nonalcoholic fatty liver disease (NAFLD) related HCC and NAFLD.
Clinical trial identification
NCT05626985.
Editorial acknowledgement
Legal entity responsible for the study
Eastern Hepatobiliary Surgery Hospital and The First Hospital of Jilin University.
Funding
Singlera Genomics Inc.
Disclosure
T. Yang: Financial Interests, Institutional, Principal Investigator: Eastern Hepatobiliary Surgery Hospital. H. Liu, H. Wang, S. Zhou, Z. Zheng, R. Liu: Financial Interests, Institutional, Full or part-time Employment: Singlera Genomics Inc. F. Shen: Financial Interests, Institutional, Principal Investigator: Eastern Hepatobiliary Surgery Hospital. G. Lv: Financial Interests, Institutional, Principal Investigator: First Hospital of Jilin University. All other authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18